sulforaphane has been researched along with Pervasive Child Development Disorders in 1 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Singh, K | 1 |
Connors, SL | 1 |
Macklin, EA | 1 |
Smith, KD | 1 |
Fahey, JW | 1 |
Talalay, P | 1 |
Zimmerman, AW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Sulforaphane in Autism: A Treatment Trial to Confirm Phenotypic Improvement With Sulforaphane Treatment in a New Jersey (NJ) Population of Individuals With Autism[NCT02677051] | Phase 2 | 48 participants (Actual) | Interventional | 2016-02-29 | Active, not recruiting | ||
Decreasing Risk of Psychosis by Sulforaphane: Study Protocol for a Randomized, Double-blind, Placebo-controlled, Clinical Multicenter Trial (DROPS Trial)[NCT03932136] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-07-14 | Recruiting | ||
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure[NCT03730649] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2019-10-09 | Recruiting | ||
Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)[NCT02561481] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
A 12-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Related Mechanism of Sulforaphane in Treatment of Autism Spectrum Disorder[NCT02879110] | 110 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
A Pilot Project to Validate Digital Bio-markers as a Tool to Measure Improvement in Core Symptoms of Autism During Sulforaphane Treatment.[NCT04805957] | 10 participants (Anticipated) | Interventional | 2022-07-07 | Enrolling by invitation | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Ohio Autism Clinical Impressions Scale-Severity (OACIS-S) rates severity of symptoms in 10 categories: general level of autism, social interaction, aberrant and repetitive behavior, verbal and nonverbal communication, hyperactivity, anxiety, sensory sensitivities and restricted and narrow interests. Each category is rated from 1 (normal) to 7 (most severe). The OACIS-S was a reference at follow up visits when the OACIS-Improvement was compared to the OACIS-S, from 1 to 7: 4 was no change; 3 to 1 minimal to marked improvement and 5 to 7 minimal to marked worsening. The numerical score of the OACIS-S is independent and unrelated quantitatively to the OACIS-I. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
7 weeks | 15 weeks | 22 weeks | 30 weeks | 36 weeks | |
Placebo | 0.28 | 0.33 | 0.59 | 0.69 | 0.29 |
Sulforaphane | 0.28 | 0.28 | 0.47 | 0.47 | 0.29 |
Aberrant Behavior Checklist (ABC) is a 58 item scale that primarily evaluates how aberrant or abnormal a patient's daily behaviors are. The items evaluate behaviors as they pertain to irritability, lethargy/social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech. Each item is scored on a scale of 0 to 3, with 0 being better outcome and 3 being worse outcome. The score from each item is added up to calculate a total score. This outcome describes change in total ABC score from baseline at each follow up visit. The scores from all items are added to calculate a total score (0 to 174). This outcome describes change in total ABC score from baseline at each follow up visit. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
7 weeks | 15 weeks | 22 weeks | 30 weeks | 36 weeks | |
Placebo | -16.23 | -11.68 | -22.4 | -10.29 | -7.8 |
Sulforaphane | -6 | -22.6 | -36.33 | -22.8 | 1.14 |
The Social Responsiveness Scale-2 (SRS-2) is a 65-item scale that measures total scores as well as subscales: four social behaviors (awareness, cognition, communication and motivation) and autistic mannerisms. Each item is rated from 1 to 4 (not true to almost always true) on worksheets that are blinded to the rater with respect to values. Total and subscale scores are calculated as raw scores and can be converted to T-scores. Raw scores (range 0-180) are reported here (unadjusted for general population, since all children had ASD). Higher or lower values at follow up visits compared to baseline indicated worsening or improvement, respectively. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
7 weeks | 15 weeks | 22 weeks | 30 weeks | 36 weeks | |
Placebo | -8.06 | -7.92 | -13.67 | -18.59 | -19.59 |
Sulforaphane | 1.14 | -16.86 | -14.61 | -19.83 | 0.80 |
F-statistic calculated by comparison of Free Reduced GSH, Total GSH and oxidized Glutathione (GSSG) of Week 15 to Week 0. (NCT02561481)
Timeframe: Week 0 and Week 15
Intervention | F-statistic (Number) | ||
---|---|---|---|
Free Reduced GSH | Total GSH | GSSG | |
Placebo | 0.11 | 0.08 | 0.46 |
Sulforaphane | 1.51 | 0.00 | 1.97 |
Cox-2 (cyclooxygenase-2): a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | -0.20 | 0.16 | -0.17 |
Sulforaphane | 0.14 | -0.07 | -0.46 |
Sulforaphane (and other isothiocyanates, ITC) are conjugated by glutathione (GSH) which then undergoes further enzymatic modifications to give rise sequentially to the cysteinylglycine-, cysteine- and N-acetylcysteine-ITC conjugates, all of which are dithiocarbamates (DTC) and are detected in the cyclocondensation reaction-HPLC assay. (NCT02561481)
Timeframe: Week 0, Week 7, Week 15, Week 22, Week 30, Week 36
Intervention | nmol DTC (Dithiocarbamates)/ml (Mean) | |||||
---|---|---|---|---|---|---|
Week 0 | Week 7 | Week 15 | Week 22 | Week 30 | Week 36 | |
Placebo | 0.006 | 0.003 | 0.005 | 0.205 | 0.214 | 0.008 |
Sulforaphane | 0.007 | 0.299 | 0.329 | 0.248 | 0.165 | 0.015 |
Ratios of free GSH:GSSG and total GSH:GSSG were calculated by obtaining ratios of f-statistic scores from baseline to week 15 between free reduced GSH and GSSG and between total GSH and GSSG. (NCT02561481)
Timeframe: Week 15
Intervention | F-statistic (Number) | |
---|---|---|
Free GSH:GSSG | Total GSH:GSSG | |
Placebo | 0.87 | 0.03 |
Sulforaphane | 12.72 | 5.16 |
HO-1 (heme oxygenase 1): an essential and Nrf2-dependent enzyme in heme catabolism. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 0.27 | 0.55 | 0.30 |
Sulforaphane | 0.10 | 0.74 | 0.74 |
HSP27 (Heat shock protein 27) was examined because it is upregulated by SF in vitro. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30.
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | -0.13 | -0.83 | -0.58 |
Sulforaphane | 0.21 | 0.21 | -0.47 |
HSP70 (Heat shock protein 70) was examined because it is upregulated by SF in vitro. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 0.99 | 1.14 | 1.20 |
Sulforaphane | 1.11 | 1.33 | 1.23 |
IL-1β: Interleukin-1 beta cytokine gene expression, a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 1.14 | 1.47 | 1.59 |
Sulforaphane | 0.90 | 1.45 | 1.50 |
IL-6 (interleukin 6) cytokine gene expression, a nuclear factor-kappa B - regulated inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 1.82 | 1.87 | 2.08 |
Sulforaphane | 1.76 | 2.05 | 1.99 |
Cytoprotective enzyme regulated by nuclear factor erythroid 2-related factor 2 (Nrf2), the master regulator of cellular redox homeostasis and an inhibitor of a key pro-inflammatory pathway, of which both functions are critical factors in the neuropathology of ASD. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 (baseline) | Week 15 | Week 30 | |
Placebo | 2.25 | 2.14 | 2.13 |
Sulforaphane | 2.23 | 2.19 | 2.15 |
See above in the primary outcome measure for a description of OACIS-I scale. This section describes the change from baseline of the OACIS-I subdomain of aberrant behaviors. This subdomain has a range of 1 to 7 - 1 is extremely improved from baseline, 7 is extremely worse from baseline, and 4 is no change. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
7 weeks | 15 weeks | 22 weeks | 30 weeks | 36 weeks | |
Placebo | 0.28 | 0.33 | 0.53 | 0.59 | 0.14 |
Sulforaphane | 0.06 | 0.22 | 0.59 | 0.63 | 0.14 |
See above in the primary outcome measure for a description of OACIS-I scale. This section describes the change from baseline of the OACIS-I subdomain of social communication. This subdomain has a range of 1 to 7 - 1 is extremely improved from baseline, 7 is extremely worse from baseline, and 4 is no change. For analysis, the OACIS-I general score and subscale values were recoded, in which 4 (no change) was recoded as 0; 3 to 1 were recoded as +1 to +3 to denote improvement, and 5 to 7 were recoded as -1 to -3 for worsening. (NCT02561481)
Timeframe: 7 weeks, 15 weeks, 22 weeks, 30 weeks, 36 weeks
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
7 weeks | 15 weeks | 22 weeks | 30 weeks | 36 weeks | |
Placebo | 0.56 | 0.56 | 1.35 | 1.25 | 0.61 |
Sulforaphane | 0.33 | 0.44 | 0.65 | 0.94 | 0.32 |
TNF-α (Tumor necrosis factor alpha), a cytokine as inflammatory biomarker. Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 0.91 | 1.08 | 1.10 |
Sulforaphane | 0.70 | 0.98 | 1.17 |
xCT (SLC7A11): Cystine/glutamate antiporter encoded by the SLC7A11 gene.Total cellular RNA was isolated from peripheral blood mononuclear cells (PBMCs) and complementary DNAs (cDNA) were synthesized. Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio™ 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Relative mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2-ΔΔCT method. (NCT02561481)
Timeframe: Week 0, Week 15, Week 30
Intervention | log fold change (Mean) | ||
---|---|---|---|
Week 0 | Week 15 | Week 30 | |
Placebo | 0.40 | 0.30 | 0.27 |
Sulforaphane | 0.24 | 0.25 | 0.24 |
1 trial available for sulforaphane and Pervasive Child Development Disorders
Article | Year |
---|---|
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |
Sulforaphane treatment of autism spectrum disorder (ASD).
Topics: Adolescent; Adult; Child Development Disorders, Pervasive; Humans; Isothiocyanates; Male; Placebos; | 2014 |